Date | Time | Source | Headline | Symbol | Company |
09/26/2024 | 8:51AM | GlobeNewswire Inc. | Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing | NASDAQ:AZN | AstraZeneca PLC |
09/26/2024 | 7:00AM | Business Wire | TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer | NASDAQ:AZN | AstraZeneca PLC |
09/23/2024 | 7:00AM | Business Wire | Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
09/23/2024 | 6:44AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
09/23/2024 | 6:32AM | IH Market News | Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More | NASDAQ:AZN | AstraZeneca PLC |
09/23/2024 | 6:27AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
09/20/2024 | 4:34PM | Business Wire | FLUMIST approved for self-administration in the US | NASDAQ:AZN | AstraZeneca PLC |
09/18/2024 | 7:00AM | Business Wire | FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis | NASDAQ:AZN | AstraZeneca PLC |
09/17/2024 | 11:22AM | GlobeNewswire Inc. | International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 | NASDAQ:AZN | AstraZeneca PLC |
09/16/2024 | 7:00AM | Business Wire | IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
09/15/2024 | 10:30AM | Business Wire | IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
09/13/2024 | 10:00AM | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases | NASDAQ:AZN | AstraZeneca PLC |
09/10/2024 | 10:28AM | PR Newswire (US) | SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing | NASDAQ:AZN | AstraZeneca PLC |
09/10/2024 | 10:16AM | PR Newswire (US) | SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing | NASDAQ:AZN | AstraZeneca PLC |
09/10/2024 | 6:02AM | IH Market News | Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9% | NASDAQ:AZN | AstraZeneca PLC |
09/09/2024 | 1:50PM | Business Wire | Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
09/08/2024 | 12:25PM | Business Wire | Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
09/05/2024 | 6:11AM | IH Market News | Qualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual Listing | NASDAQ:AZN | AstraZeneca PLC |
09/03/2024 | 7:00AM | Business Wire | AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024 | NASDAQ:AZN | AstraZeneca PLC |
08/23/2024 | 8:20AM | IH Market News | Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1% | NASDAQ:AZN | AstraZeneca PLC |
08/16/2024 | 7:00AM | Business Wire | IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery | NASDAQ:AZN | AstraZeneca PLC |
08/16/2024 | 6:21AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
08/15/2024 | 7:00AM | Business Wire | IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US | NASDAQ:AZN | AstraZeneca PLC |
07/30/2024 | 6:26AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
07/30/2024 | 6:00AM | IH Market News | Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots | NASDAQ:AZN | AstraZeneca PLC |
07/29/2024 | 7:00AM | Business Wire | Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
07/29/2024 | 6:00AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
07/25/2024 | 7:00AM | Business Wire | AstraZeneca’s H1 and Q2 2024 Financial Results | NASDAQ:AZN | AstraZeneca PLC |
07/25/2024 | 6:21AM | IH Market News | U.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire Expectations | NASDAQ:AZN | AstraZeneca PLC |
07/25/2024 | 6:19AM | IH Market News | Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5% | NASDAQ:AZN | AstraZeneca PLC |